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OBJECTIVE — Acute, short-term hyperglycemia enhances high shear stress–induced plate-
let activation in type 2 diabetes. Several observations suggest that platelets in type 2 diabetes are
resistanttoinhibitionbyaspirin.Ouraimwastoassesscomparativelytheeffectofaspirin,anitric
oxide–donatingagent(NCX4016),theircombination,orplaceboonplateletactivationinduced
by acute hyperglycemia in type 2 diabetes.
RESEARCH DESIGN AND METHODS — In a double-blind, placebo-controlled, ran-
domized trial, 40 type 2 diabetic patients were allocated to 100 mg aspirin once daily, 800 mg
NCX 4016 b.i.d., both of them, or placebo for 15 days. On day 15, 1 h after the morning dose,
a 4-h hyperglycemic clamp (plasma glucose 13.9 mmol/l) was performed, and blood samples
were collected before and immediately after it for platelet activation and cyclooxygenase-1
(COX-1) inhibition studies.
RESULTS — Acute hyperglycemia enhanced shear stress–induced platelet activation in pla-
cebo-treated patients (basal closure time 63  7.1 s, after hyperglycemia 49.5  1.4 s, 13.5 
6.3 s, P  0.048). Pretreatment with aspirin, despite full inhibition of platelet COX-1, did not
prevent it (12.7  6.9 s, NS vs. placebo). On the contrary, pretreatment with the NO donor
NCX4016,aloneorincombinationwithaspirin,suppressedplateletactivationinducedbyacute
hyperglycemia (NCX 4016 10.5  8.3 s; NCX 4016 plus aspirin: 12.0  10.7 s, P  0.05
vs. placebo for both). Other parameters of shear stress–dependent platelet activation were also
more inhibited by NCX 4016 than by aspirin, despite lesser inhibition of COX-1.
CONCLUSIONS — Acute hyperglycemia-induced enhancement of platelet activation is re-
sistant to aspirin; a NO-donating agent suppresses it. Therapeutic approaches aiming at a wider
platelet inhibitory action than that exerted by aspirin may prove useful in patients with type 2
diabetes.
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T
ype 2 diabetes is associated with a
two-tofourfoldincreasedincidence
of ischemic cardiovascular events
andmarkedlyenhancestheriskofstroke,
amputation,anddeath(1).Notonlylong-
term, continuous hyperglycemia but also
transient, acute hyperglycemic spikes
maycontributetothepoorcardiovascular
prognosis of patients with type 2 diabetes
(2).
Platelet hyperreactivity has been
identiﬁed as one of the mechanisms of
enhancedarterialthrombosisintype2di-
abetes (3). We have previously shown
that in type 2 diabetes an acute, short-
term hyperglycemia enhances platelet ac-
tivation, and, in particular, high-shear
stress–induced activation, which is con-
sidered an important mechanism trigger-
ing arterial thrombosis (4). This
phenomenon is partly due to acute en-
hancement of the circulating levels of von
Willebrand factor (vWF) (4) and indeed
platelet-plasma interactions involving
vWF have been previously suggested to
cause increased platelet aggregability (5),
and recent epidemiological data show
that plasma vWF predicts cardiovascular
eventsinpatientswithtype2diabetes(6).
High shear stress–induced platelet activa-
tion is hardly sensitive to inhibition by
aspirin, and this has been advocated as
one of the reasons for the high residual
incidence of ischemic events in patients
with acute coronary syndromes treated
with aspirin (7). The effectiveness of aspi-
rinasanantiplateletagentinpatientswith
type2diabetesisbeingincreasinglyques-
tioned and aspirin nonresponsiveness,
i.e., the incomplete inhibition of platelet
aggregation upon chronic aspirin intake,
has been documented in type 2 diabetes
(3,8). In the antithrombotic trialists’ col-
laboration overview in patients at risk of
ischemiccardiovascularevents,antiplate-
let therapy did not reduce the odds of a
vascular event in diabetes (7%), differ-
ent from the highly signiﬁcant reduction
produced in the overall population at risk
(25%) (9).
Nitric oxide (NO), a naturally occur-
ring antiatherothrombotic mediator, in-
hibitstheaggregationofplateletsinduced
by all agonists, also suppressing aspirin-
resistant pathways. The production of
NO is defective in patients with type 2
diabetes (5). It seems thus logical to test
NO-donating agents for their effect on
platelet activation in type 2 diabetes.
NCX 4016 (2-(acetyloxy)benzoic ac-
id-3-[(nitrooxy)methyl]phenyl ester), a
NO-donating moiety linked to an acetyl-
salicylicacidbackbone,isaprototypeofa
seriesofNO-donatinghybriddrugsofpo-
tential use for cardiovascular disorders
(10). NCX 4016 was shown to display a
wide range of antiplatelet activities in
vitro and in vivo (11) and to release bio-
logically relevant amounts of NO after
oral administration to humans (12,13).
Based on the above considerations,
we have compared aspirin with the NO-
donatingagentNCX4016fortheireffects
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acute, short-term hyperglycemia in pa-
tients with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Forty patients with
type 2 diabetes, as deﬁned by the Ameri-
can Diabetes Association criteria, were
enrolled in a randomized, double-blind,
double-dummy,parallelgroups,placebo-
controlled study. Enrollment criteria
were the following: male and female pa-
tients (age range 18–75 years) affected by
type 2 diabetes (duration of disease 10
years) and having stable metabolic con-
trol (A1C in the range of 7–8%) with diet
and oral antidiabetic treatment, and sta-
ble blood pressure control (130–80
mmHg) if hypertensive.
Concomitant treatments with anti-
plateletdrugsornitrateswerenotallowed
inthe10daysbeforerandomization.ACE
inhibitors,angiotensinIIantagonists,and
statins were allowed only if they had been
taken regularly for 3 months before en-
rollment and were continued throughout
the study.
Patients were randomly assigned to
one of the following treatments: 100 mg
aspirin once daily plus placebo, 800 mg
NCX 4016 b.i.d. plus placebo, aspirin
plus NCX 4016, or placebo for 15 days. A
treatment using the combination of aspi-
rin and NCX 4016 seemed appropriate
because most of the new antiplatelet
agents that more recently entered clinical
use have been tested along with aspirin
and because previous studies have shown
that thromboxane (Tx) A2 synthesis inhi-
bition after oral NCX 4016 is less than
optimal (11).
Patients were instructed to take one
sachet (NCX 4016 or placebo) and one
tablet (aspirin or placebo) in the morning
after breakfast, and one sachet (NCX
4016 or placebo) in the evening after din-
ner. The last study drug medication was
takeninthemorningofday15,1hbefore
the start of the clamp procedure. A 4-h
hyperglycemic clamp was performed as
described previously (4). In brief, glucose
was infused at a variable rate, based on
plasma glucose measured every 5 min, to
maintain steady-state plasma glucose lev-
els (250 mg/dl, 139 mmol/l). Plasma glu-
cose was measured with a glucose
analyzer (Glucose Analyzer II; Beckman
Instruments, Fullerton, CA), plasma in-
sulinandC-peptideweremeasuredbyas-
says described previously (4), and A1C
was measured by high-performance liq-
uid chromatography, using an H1-
AutoA1c HA 8121 apparatus (DIC, Kyoto
Daiichi, Kogaku Co., Japan). Blood for
plateletfunctionstudieswascollectedbe-
fore and at the end of the clamp proce-
dure. A bleeding time test was performed
before blood sampling preclamp and
again after blood sampling postclamp.
Urine samples were collected for the fol-
lowing periods: the 24 h ending at the
start of the clamp (preclamp), the4ho f
the clamp procedure (clamp), and the
24 h starting from the beginning of the
clamp (postclamp). The study was ap-
proved by our institutional review board
(Comitato Etico delle Aziende Sanitarie
dell’Umbria), and all patients gave in-
formed, witnessed, written consent be-
fore enrollment.
Laboratory methods
Bleeding time. A standardized bleeding
timetestwasperformedusinganautomatic
template device (Simplate II) as described
previously (14). The blood emerging from
the skin wound was collected on a chilled
antiplatelet-anticoagulant mixture (citrate,
theophylline, adenosine, and dipyridam-
ole) for the quantiﬁcation of platelet activa-
tion, as described (14).
Shear-induced platelet activation.
Shear-induced platelet activation was as-
sessed with the O’Brien ﬁltration test (15)
as described previously (4). Filter closure
time and percentage of platelets retained
were measured (4).
Platelet adhesion to collagen under
ﬂow conditions. Platelet adhesion to a
collagen-coated surface was studied in a
perfusion chamber as described previ-
ously (4). In brief, citrated blood (5 ml)
was passed through a rectangular parallel
plate perfusion chamber over a plastic
coverslip sprayed with collagen from
equine tendon (30 g/cm
2; Mascia
Brunelli,Milano,Italy),atawallshearrate
of 3,000 s
1. The coverslip was then har-
vested, gently washed with 10 mmol/l
HEPES, placed in 400 l of a lytic buffer
for 1 h, and then frozen and thawed three
times. The supernatants were stored at
80°C until assayed for -thromboglob-
ulin by an ELISA assay (Asserachrom
-TG; Roche Diagnostics, Monza, Italy)
(16).Thetotalnumberofplateletsdepos-
ited on the coverslip was calculated by
dividing the amount of -thromboglobu-
lin present in the lysate by that present in
a known number of nonactivated plate-
lets of the same patient. Results are ex-
pressed as number of platelets deposited
per square micrometer (16).
Light transmission platelet aggregom-
etry. Platelet aggregation induced by ar-
achidonic acid (0.3, 0.4, and 1 mmol/l)
and by collagen (1 g/ml) was studied
with the photometric method as de-
scribed previously (4), and the maximal
amplitude of aggregation was recorded at
3 min.
Platelet activation by ﬂow cytometry.
Flow cytometric analysis of activated
platelets was performed in samples from
peripheral venous blood and from the
whole blood emerging from the bleeding
time wounds by assessing the expression
on platelets of the activation antigen P-
selectin (4) and the binding of monoclo-
nal antibody PAC-1, which recognizes
activatedglycoproteinIIb/IIIa(4,14).The
presence of circulating platelet-leukocyte
aggregates in venous blood was assessed
byﬂowcytometryasdescribedpreviously
(17).
von Willebrand factor. vWF activity
was measured in citrated plasma with a
system(vWFActivityKit;ShieldDiagnos-
tic,Dundee,U.K.)thatusesamonoclonal
antibody recognizing an epitope of vWF
involvedintheinteractionwithglycopro-
teinIb	.Resultsareexpressedaspercent-
age of control (4).
Plasmatic nitrite plus nitrate. Plasma
levels of NO degradation products, ni-
trites plus nitrates, were measured by the
Griess reagent method (12).
Platelet-derived Tx. Serum TxB2 was
measured by radioimmunoassay as
described previously (18). The urinary
excretion of 11-dehydro-TxB2 was evalu-
ated by a previously validated radioim-
munoassay technique as described (4).
Statistical analysis
The sample size was calculated, based on
the results of a previous study (4), using
theﬁlterclosuretimeintheO’Brienﬁltra-
tion test as a primary end point and as-
suming that a mean  SD difference of
6.5  6 s between the active treatment
(NCX 4016) and placebo would occur
withapowerof80%andaone-sided	

0.05. Based on these assumptions, 10 pa-
tients per group had to be enrolled. Pa-
tients were randomly assigned to one of
the four treatment groups using a com-
puter-generated random scheme.
Statistical analysis was performed us-
ing SAS system software. ANOVA was
performedtotestdifferencesbetweendif-
ferent time points and between treat-
ments. Data are expressed as means 
SEM. P  0.05 was considered as
signiﬁcant.
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Patients
The demographic data of the patients en-
rolledinthestudyarereportedinTable1.
No signiﬁcant differences in any of the
demographic parameters were evident
between the treatment groups. Fasting
plasma glucose and insulin concentra-
tions before the clamp were not different
in the four study groups. After the begin-
ning of glucose infusion, plasma glucose
reachedthetargetof250mg/dlby31.6
2.2 min, with no differences between
groups (Fig. 1A). Plasma insulin in-
creased in response to hyperglycemia
(baseline 
 12.1  0.8 U/ml and
steady-state 
 28.0  4.2 U/ml) with
no signiﬁcant differences between the
groups, although with a trend to higher
insulin levels upon hyperglycemia in the
NCX4016–treatedgroups.Plateletcount
was similar before the clamp in the four
study groups and decreased slightly, but
not signiﬁcantly, after the clamp. Hemat-
ocrit values were similar at baseline in all
study groups and remained unchanged
after the clamp.
Bleeding time
Average baseline bleeding time (before
clamp)was415.130.0s(n
40),with
no signiﬁcant differences among the four
groups, although a trend toward a longer
bleeding time was observed in the aspirin
plus NCX 4016 group (535  32.5 s vs.
placebo 
 373.5  30.9 s, NS). Four
hours of hyperglycemia shortened
slightly, but signiﬁcantly, the bleeding
time in the placebo group (325.5  20 s,
P 
 0.02), conﬁrming previous data (4).
In the NCX 4016 and NCX 4016 plus
aspirin groups the bleeding time was un-
changedaftertheclampprocedure.Inthe
aspirin group, a prolongation of the
bleeding time was found after the clamp
(from 369.5  34.5 to 439  45.2 s, P 

0.03).
Shear-induced platelet activation
Platelet activation in the O’Brien test did
not differ among the four different treat-
ment groups at baseline (before clamp)
(average ﬁlter closure time 61.9  6.3 s;
retained platelets 78  6.3%, n 
 40).
The hyperglycemic clamp signiﬁcantly
shortened the ﬁlter closure time and en-
hanced the percentage of platelets re-
tained in the placebo group (Fig. 1B and
C). Aspirin treatment did not affect the
enhancing action of acute, short-term hy-
perglycemia on shear stress–induced
platelet activation, with a persistence of
the shortening of the ﬁlter closure time
after the clamp and of the increase of the
percentage of retained platelets. Treat-
ment with NCX 4016 or with NCX 4016
plusaspirin,instead,reversedtheeffectof
hyperglycemia on both the ﬁlter closure
time and on the percentage of retained
plateletswithastatisticallysigniﬁcantdif-
ference compared with both the aspirin
and the placebo groups (P 
 0.038 and
P 
 0.043, respectively) (Fig. 1B and C).
Comparing the overall NCX 4016–
treated groups, i.e., cumulating the two
groups who received NCX 4016 alone or
in combination, with the groups not re-
ceiving NCX 4016 (placebo and aspirin),
differenceswerestatisticallyhighlysignif-
icant for both ﬁlter closure times (P 

0.0046) and percentage of platelets re-
tained (P 
 0.0169), indicating a NCX
4016–related effect on shear-induced
platelet activation (Fig. 1B and C).
Platelet deposition on collagen at
high shear rate
Platelet deposition on collagen did not
differ among the four treatment groups at
baseline (before clamp) (average 

99.4  6.3 platelets/m
2, n 
 40). Acute
hyperglycemia signiﬁcantly enhanced
platelet deposition in the placebo-treated
group (7.1  3.2 platelets/m
2)( P 

0.01 vs. preclamp). Both NCX 4016 and
aspirin, although the latter to a smaller
extent, reversed the enhancing activity of
acute hyperglycemia on platelet deposi-
Table 1—Demographic data of the patients enrolled
ASA NCX 4016
ASA  NCX
4016 Placebo All patients
Age (years) 62.1  9.2 56.2  7.7 60.1  6.9 60.0  8.9 59.4  8.4
Male sex (%) 90 70 70 70 75
BMI (kg/m
2) 29.8  3.7 30.6  4.1 29.3  2.3 28.8  2.4 29.6  3.1
Fasting plasma glucose (mg/dl) 113.6  10 116.9  14 105.6  5.4 124.1  16.2 115  13.2
Plasma insulin (U/ml) 13  1.0 12.3  2.2 15.3  2.2 12  1.2 13.1  0.9
C-Peptide (ng/ml) 2.7  1.6 1.9  1.2 2.1  1 1.9  1 2.2  1.2
A1C (%) 7.2  09 7.7  08 7.8  0.4 7.4  0.4 7.5  0.6
Arterial hypertension (%) 40 80 70 70 65
ACE inhibitors (n)5 6 4 5 2 0
ATII antagonists (n)4 0 1 2 7
Doxazosine (n)0 0 1 1 2
Ca Channels Blockers (n)4 4 2 1 1 1
Diuretics (n)1 4 4 2 1 1
Hypertriglyceridemia (%) 40 40 50 70 50
Antidiabetic therapy (n)
Diet 1 0 2 1 4
Insulin 6 5 2 5 18
Metformin 2 7 4 5 18
Repaglinide 1 1 3 0 5
Sulfonylureas 1 2 1 0 4
Statins (n)2 * 1 * 1 † 1 * 5
No signiﬁcant differences were found between the four groups for any of the indicated parameters. *Atorvastatin, †simvastatin.
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pared with placebo for NCX 4016 (Fig.
1D). Combined treatment with aspirin
and NCX 4016, although producing a
trendtowardareversaloftheplateletdep-
osition–enhancing effect of acute hyper-
glycemia, did not modify it signiﬁcantly
compared with placebo (Fig. 1D).
Platelet aggregation
Arachidonic acid induced a dose-related
increase of platelet aggregation in the pla-
cebo group, which was not signiﬁcantly
affected by the hyperglycemic clamp,
conﬁrming previous data (4) (supple-
mentary Fig. 1, available in an online ap-
pendix at http://care.diabetesjournals.org/cgi/
content/full/dc09-2013/DC1). Arachidonic
acid–inducedplateletaggregationatbase-
line (preclamp) was signiﬁcantly inhib-
ited in the three active treatment groups
compared with placebo, although signiﬁ-
cantly less in the NCX 4016 group when
the highest concentration of arachidonic
acid (1 mmol/l) was used (supplementary
Fig. 1A).
The inhibition of platelet aggregation
in the three active treatment groups was
unaffected by the hyperglycemic clamp,
except for the NCX 4016 group in which
the inhibition of aggregation induced by
the highest concentration of arachidonic
acid (1 mmol/l) after the clamp was no
longer less than that in the other two ac-
tive treatment groups (supplementary
Fig. 1A). The lack of effect of NCX 4016
on platelet aggregation induced by high
concentrations of arachidonic acid in the
sample taken before the clamp, but no
longer evident in the sample taken after
the clamp, can be explained by the fact
that NCX 4016 has a slower absorption
rate than aspirin (13), and this may trans-
late in incomplete inhibition of TxB2 pro-
duction before the clamp, but not after.
Collagen-induced platelet aggregation
was signiﬁcantly inhibited in the aspirin
and NCX 4016 plus aspirin groups but
not in the NCX 4016 group (supplemen-
tary Fig. 1B). Acute hyperglycemia did
notaffectcollagen-inducedplateletaggre-
gation in any of the treatment groups,
conﬁrming previous data (4). The obser-
vation that collagen-induced light trans-
mission aggregometry was not
signiﬁcantly inhibited by NCX 4016
whereasitwasbyaspirinand,onthecon-
trary, that platelet deposition on collagen
at a high shear rate was inhibited more
extensively by NCX 4016 than by aspirin
canbeexplainedbythefactthatlow-dose
collagen-induced aggregation is largely
dependent on TxA2 production, which is
Figure 1—A: Plasma glucose concentrations before and during the 4-h hyperglycemic clamp in the four treatment groups. No differences between
groups were observed at any of the observation times. B and C: Shear stress–induced platelet activation using the O’Brien ﬁltration test. Data are
expressed as differences () between the values observed after the 4-h hyperglycemic clamp (post) and the values observed before (pre). B: Filter
closure time expressed in seconds. C: Platelets retained between 20 and 40 s, expressed as a percentage of the platelet count before ﬁltration. In the
insets are reported results cumulating the two groups receiving NCX 4016 (w NCX) and the two groups not receiving it (w/o NCX). Data are
expressed as means  SEM. *P  0.05 vs. placebo; §P  0.05 vs. aspirin (ASA); #P  0.05 vs. w/o NCX 4016. D: Platelet deposition on a
collagen-coated surface under high shear rate (3,000 s
1). Data are expressed as differences () between the values observed after the 4-h
hyperglycemic clamp (post) and the values observed before (pre). *P  0.001 versus placebo.
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below), whereas platelet adhesion at a
high shear rate is very sensitive to NO
inhibition and hardly to aspirin (7,11).
Flow cytometry
Platelet activation markers in venous
blood. P-selectin expression on platelets
in venous blood was similar in the four
groups at baseline (preclamp) (average
1.5  0.2% of positive platelets) and was
notmodiﬁedbythehyperglycemicclamp
in any of the four groups, conﬁrming pre-
vious results (4). Similar data were ob-
tained concerning the expression of
PAC-1 on platelets circulating in venous
blood (data not shown).
Platelet activation in bleeding time
blood. At baseline, preclamp, the ex-
pression of P-selectin on platelets in
bleeding time blood increased progres-
sively over time, consistent with ongoing
platelet plug formation, as reported pre-
viously (4,14) (Fig. 2A). The size of this
increase at baseline did not differ among
the four treatment groups.
P-selectin expression on platelets in
bleeding time blood was signiﬁcantly en-
hanced after the hyperglycemic clamp in
the placebo group, conﬁrming previous
data (4), whereas in all the active treat-
ment groups it was unchanged or de-
creased postclamp, with no substantial
differencebetweenNCX4016andaspirin
(Fig. 2B).
Circulating platelet-leukocyte aggre-
gates. Circulating platelet-leukocyte ag-
gregates did not differ among the four
groups at baseline. Four hours of hyper-
glycemia induced a signiﬁcant increase in
circulating platelet-leukocyte aggregates
in the placebo-treated group (from
3.750.7to5.51.0%,P0.05).The
hyperglycemia-induced increase in circu-
lating platelet-leukocyte aggregates was
not affected by aspirin (1.89  2.09%,
NS vs. placebo), whereas it was signiﬁ-
cantly reduced by treatment with NCX
4016 (0.50  0.38%, P 
 0.039 vs.
placebo). Treatment with NCX 4016 plus
aspirin also reduced the increase of circu-
lating platelet-leukocytes aggregates in-
duced by hyperglycemia, but not
signiﬁcantly compared with placebo
(0.38  0.60%, NS vs. placebo).
vWF activity. vWF activity was similar
in the four groups at baseline, and it in-
creased signiﬁcantly after clamp in the
placebo group (preclamp 77.6  4.1%,
postclamp 91.4  5.7%, 13.8  4.5%,
P 
 0.014). Treatment with NCX 4016
and with aspirin produced a slight de-
crease of vWF activity after the clamp
(13.8  7.9%, P0.01 and 10.4 
12.1%, NS), whereas the combination of
NCX 4016 and aspirin did not affect the
Figure2—A:Plateletactivationinbleeding-timebloodasassessedbytheexpressionofP-selectinonthesurfaceofplateletsinthebloodoozingfrom
the skin wound in the placebo group before the clamp. Time 0 indicates the levels detected in venous blood (not activated platelets). B: P-selectin
expressiononplateletsinthefourtreatmentgroupsbefore(Œ)andafter()theclamp.*P0.05vs.placebo.CandD:Platelet-derivedthromboxane
in the four treatment groups. C: Serum TxB2. D: Urinary excretion of 11-dehydro-TxB2.* P  0.05 vs. placebo; §P  0.05 vs. aspirin; #P  0.05,
at least, vs. preclamp; §P  0.05 vs. aspirin.
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the hyperglycemic clamp (12.4 
10.6%, NS).
Plasmatic nitrite plus nitrate. Plas-
matic nitrite plus nitrate (NOx) levels be-
fore the clamp in the four treatment
groups were: placebo 49.1  4.6 mol/l,
aspirin 55.3  11.5 mol/l (NS vs. pla-
cebo), NCX 4016 66.9  11.6 mol/l
(P 
 0.05 vs. placebo), and NCX  aspi-
rin 97.7  7.2 mol/l (P 
 0.002 vs.
placebo).
Platelet-derived TxB2. Baseline serum
TxB2(beforeclamp)wassigniﬁcantlyand
strikingly inhibited in all treatment
groups compared with that treated with
placebo, although signiﬁcantly less in the
NCX 4016–treated group than in the as-
pirin-treatedgroup(Fig.2C).Urinary11-
dehydro-TxB2 excretion in the placebo
group before the clamp was 2,090 
209.9 pg/mg creatinine, a value clearly
enhanced compared with that in healthy
subjects studied simultaneously in our
laboratory (200–500 pg/mg creatinine)
and increased signiﬁcantly during the
clamp (2,264  282.8 pg/mg creatinine,
P0.05 vs. preclamp) and in the 24 h
after the beginning of the clamp
(2,445.1  344.8 pg/mg creatinine, P 

0.001 vs. preclamp). Preclamp urinary
11-dehydro-TxB2 excretion was signiﬁ-
cantlylowerinallactivetreatmentgroups
than that in the placebo group (368.4 
39.4 pg/mg creatinine for the aspirin
group, 876.8  121 pg/mg creatinine for
the NCX 4016 group, and 567.7  61
pg/mg creatinine for the NCX 4016as-
pirin group): and was unaffected by the
clamp procedure (Fig. 2D).
Safety. Blood pressure and heart rate
were not signiﬁcantly changed at day 15
comparedwiththoseatday0inanyofthe
treatment groups and laboratory tolera-
bility markers were not signiﬁcantly
changed. One duodenal ulcer was re-
corded in the aspirin group after 14 days
of treatment.
CONCLUSIONS — This study
shows that acute short-term hyperglyce-
mia induces a rapid and signiﬁcant in-
crease of high shear stress–induced
platelet activation in patients with type 2
diabetes, conﬁrming previous results (4).
This result is documented by the en-
hancedshearstress–inducedplateletacti-
vation, enhanced platelet deposition to
collagen at high shear rate, increased ex-
pressionofanactivationantigenonplate-
lets in the bleeding time blood, and
increased urinary excretion of 11-
dehydro-TxB2,amarkerofinvivoplatelet
activation. Parameters of platelet func-
tion, which are not shear-dependent like
light transmission aggregometry or the
expressionofactivationantigensonplate-
lets circulating in venous blood, did not
change after short-term hyperglycemia
(4).
Highshearstress–inducedplateletac-
tivation is considered to be a parameter
relevantforarterialthrombosismorethan
light transmission aggregometry, and it
has been reported to be insensitive to in-
hibition by aspirin in vitro (7). No stud-
ies, however, have addressed the effect of
aspirin intake on high shear stress–
induced platelet activation, especially in
diabetic individuals. Because NO is able
toinhibithighshearstress–inducedplate-
let activation (19), we set up a study to
compare aspirin and an NO donor, NCX
4016, for their capability to prevent the
acute hyperglycemia-induced platelet ac-
tivation in patients with type 2 diabetes.
We found that the enhancement of
shear stress-induced platelet activation
causedbyhyperglycemiaisnotprevented
by aspirin, despite adequate suppression
of platelet cyclooxygenase-1 (COX-1),
whereas it is completely suppressed by a
NO-donating agent. In fact, although in
patients treated with aspirin ﬁlter closure
time was shortened and the percentage of
retained platelets was increased by acute
hyperglycemia to an extent similar to that
observed in placebo-treated subjects, in
diabetic individuals treated with NCX
4016 these parameters of platelet activa-
tion were unchanged or even reduced
after acute hyperglycemia. Acute hyper-
glycemia also enhanced other parameters
ofplateletactivation,suchasplateletdep-
osition on collagen at a high shear rate or
the formation of platelet-leukocyte aggre-
gates in circulating blood, and these were
also consistently reduced by NCX 4016
but not by aspirin.
The baseline urinary excretion of 11-
dehydro-TxB2, a marker of in vivo TxA2
generationintheplacebo-treateddiabetic
subjects, was strikingly increased com-
pared with that in our reference healthy
control group. This result is consistent
with the results of previous studies show-
ing that diabetic patients excrete large
amounts of urinary TxA2 metabolites es-
pecially in the presence of poor glycemic
control, most of which derive from plate-
lets as an expression of increased in vivo
platelet activation, being markedly re-
ducedbylowdosesofaspirin(20).Short-
term hyperglycemia further increased
urinary 11-dehydro-TxB2 excretion, con-
ﬁrming increased activation of platelets
exposed in vivo to high shear stress in
diabetic individuals (4). Although all ac-
tive treatments inhibited serum TxB2 and
urinary excretion of 11-dehydro-TxB2
signiﬁcantly compared with placebo,
NCX 4016 did so signiﬁcantly less than
aspirinandnotquitetotheextent(95%
inhibition of serum TxB2) considered to
be required for the effective suppression
of in vivo platelet activation (21). The ob-
servation that despite incomplete sup-
pression of platelet COX-1, NCX 4016
inhibited several parameters of ex vivo
and in vivo platelet activation in diabetic
individuals suggests that the antiplatelet
activity exerted was largely due to the re-
leased NO. Indeed, NCX 4016, but not
aspirin, enhanced plasma levels of NOx,
demonstrating the delivery of NO in vivo
(12). Considering that NCX 4016 in vitro
inhibits platelet COX-1 irreversibly and
with a potency similar to that of aspirin
(18), the lower inhibition we found in
vivosuggeststhatonlyaminorfractionof
NCX 4016 is absorbed as such after oral
administration (13).
Hyperglycemia may contribute to
atherosclerotic complications in patients
with type 2 diabetes not only when it is
sustained but also when it occurs in
spikes, as in the postprandial state (2):
our ﬁndings suggest that the enhance-
ment of in vivo platelet activation during
acute hyperglycemia may be one of the
effectors of cardiovascular complications.
Indeed,intensiveglycemiccontrolintype
2 diabetes results in reduced mortality
and myocardial infarction (22). Our
study,usingamodelresemblingthepost-
prandialhyperglycemiaoftype2diabetes
in terms of glucose and insulin plasma
levels, suggests that platelet hyperreactiv-
ity is involved in the detrimental cardio-
vascular effects of hyperglycemic spikes
and shows that aspirin is not able to
preventit,supportingtheconceptthatas-
pirin offers a less than optimal cardiovas-
cular protection in diabetic patients
(3,8,9). NO has been known for more
than two decades as a very effective plate-
let function inhibitor, but the search for
drugs able to release it in vivo in biologi-
cally relevant amounts without incurring
inuntowardeffectshasbeensofarunsuc-
cessful elusive (23).
The present results with NCX 4016
show that it is possible to release NO in
vivo in amounts sufﬁcient to inhibit the
platelet hyperactivity induced by acute
hyperglycemia in diabetic patients with-
Gresele and Associates
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showing that NCX 4016 stimulates glu-
cose transport in adipocytes without neg-
atively affecting insulin sensitivity and
that it could therefore help in better con-
trolling glycemia (24) further suggest that
NCX 4016 may be suitable for patients
with type 2 diabetes. However, NCX
4016 is poorly absorbed and has limita-
tions of pharmaceutical formulation that
prevent its further clinical development.
Novel hybrid molecules able to exert a full
aspirin effect and/or to produce larger or
moresustainedNOreleasemayexertstron-
ger antiplatelet action and thus represent
ideal candidates for development in pa-
tients with type 2 diabetes. Agents poten-
tiallyofferingthesecharacteristicsareunder
study (25).
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